Hemab Therapeutics Holdings (COAG) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
0 of 1 scored quarter beat.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Reaction |
|---|---|---|---|---|---|---|
| Nov 10, 20268-K, before open · 7:00 am ET | −0.50adjusted basis | −0.58 | —a Withheld: the reported earnings per share fall well short of the estimate while revenue does not, the usual sign of an adjusted estimate set against reported earnings. | $0.00 | $0.00 | −9.4%release day |
| Aug 11, 20268-K, before open · 7:11 am ET | −0.73b Scored against the latest consensus we hold for this quarter, stored after the report; our record does not reach back to the night before it. | −0.80 | −9.2% | $0.00 | $0.00 | +3.7%release day |
| May 21, 20268-K, before open · 7:05 am ET | — | −23.98 | — | — | $0.00 | −0.6%release day |
| Nov 4, 2025 E | — | −18.04 | — | — | $0.00 | —estimated date |
| Aug 4, 2025 E | — | −12.91 | — | — | $0.00 | —estimated date |
| May 5, 2025 E | — | −16.18 | — | — | $0.00 | —estimated date |
- a Withheld: the reported earnings per share fall well short of the estimate while revenue does not, the usual sign of an adjusted estimate set against reported earnings.
- b Scored against the latest consensus we hold for this quarter, stored after the report; our record does not reach back to the night before it.
None of the 6 quarters above is scored against a consensus we stored the night before its report; 1, marked b, is scored against the latest consensus we hold, stored after the report, which may have moved toward the result. 4 reported before we stored a consensus for them, so they are not scored. 1 is not scored for the reason marked beside it.
E marks a report date we estimated from the fiscal period end, because we found no results release and no usable filing date for that quarter. Those rows show no reaction: a move measured from a day we guessed is not a reaction to the release, and we would rather leave it blank than publish it.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 3 | 2 | 4 | 4 |
| Avg estimate | −0.57 | −0.61 | −3.01 | −2.56 |
| Low estimate | −0.60 | −0.62 | −3.08 | −2.76 |
| High estimate | −0.54 | −0.60 | −2.92 | −2.36 |
| Year-ago EPS | — | −23.98 | — | −3.01E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 0 | 0 | 0 | 0 |
| Avg estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Low estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| High estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Year-ago revenue | — | $0.00 | — | $0.00E |
| Implied growth | — | — | — | — |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.57 | −0.61 | −3.01 | −2.56 |
| 7 days ago | −0.57 | — | −2.99 | −2.53 |
| 30 days ago | −0.55 | — | −3.05 | −2.47 |
| 60 days ago | −0.57 | — | −3.10 | −2.54 |
| 90 days ago | −0.57 | — | −2.86 | −2.48 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus has held at −$0.57 across 90 tracked days since Aug 14, 2026. A bar that has not moved is an answer, not a gap: a beat against a flat bar is a real beat. Per-analyst up/down revision counts aren't in our data feed.
Common questions
What were Hemab Therapeutics Holdings' latest quarterly earnings?
Hemab Therapeutics Holdings reported diluted EPS of −0.58 and revenue of $0.00 on Nov 10, 2026.
How did Hemab Therapeutics Holdings' stock move after its last earnings report?
Hemab Therapeutics Holdings moved −9.4% in the session after its Nov 10, 2026 report.

